Physician profile
Angela Persohn
NPI 1619326402
$6,101.31
in general payments reported to CMS, 2019-2025
39 companies · $1,761 in 2025
The $1,761 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $665 · 2022: $1,153 · 2023: $1,148 · 2024: $1,374 · 2025: $1,761.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,282.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $908.66 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $676.75 | 2021-2025 | |
| Lilly USA, LLC | $615.44 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $430.83 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $427.89 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $299.04 | 2021-2025 | Repatha, Repatha, Evenity |
| Glaxosmithkline, LLC. | $281.87 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Mylan Specialty L.P. | $216.24 | 2021-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $201.36 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.56 | 2021-2024 | Jardiance |
| Novartis Pharmaceuticals Corporation | $167.43 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $165.23 | 2023-2025 | Caplyta |
| Merck Sharp & Dohme LLC | $161.05 | 2021-2025 | Verquvo, Belsomra, Steglatro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $120.96 | 2021-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $119.57 | 2021-2024 | Freestyle Libre 3 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $106.71 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $106.62 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Otsuka America Pharmaceutical, INC. | $96.84 | 2022-2025 | Rexulti |
| Viatris Specialty LLC | $94.01 | 2025 | Yupelri |
| Astellas Pharma US INC | $86.26 | 2021-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $83.76 | 2021-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $82.62 | 2021-2025 | Trintellix |
| Axsome Therapeutics, INC. | $67.92 | 2024-2025 | Auvelity |
| Biohaven Pharmaceutical Holding Company LTD. | $66.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $36.90 | 2021 | |
| Phathom Pharmaceuticals, INC. | $34.71 | 2024 | Voquezna |
| Nevro Corp. | $32.96 | 2021-2023 | Senza |
| Dexcom, INC. | $31.06 | 2024-2025 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $29.83 | 2025 | Inspire |
| Eisai INC. | $29.28 | 2021-2022 | |
| Amarin Pharma, INC. | $28.37 | 2021 | |
| Medtronic, INC. | $24.07 | 2025 | Minimed 780g |
| Vertex Pharmaceuticals Incorporated | $18.51 | 2025 | |
| Lundbeck LLC | $15.73 | 2025 | Rexulti |
| Kci USA, INC. | $14.13 | 2022 | |
| Amneal Pharmaceuticals LLC | $13.83 | 2021 | |
| Sanofi-Aventis U.S. LLC | $12.01 | 2022 | |
| Adlon Therapeutics L.P. | $11.70 | 2021 | |
| Corium, LLC | $10.48 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Persohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.